MedTrace Logo

MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer

NCT01972919 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2026-05-12

Study results available
· View outcomes & findings →

Summary

This research study is for people who have pancreas cancer for which surgery is not recommended. Potential patients must have already received several months of chemotherapy before they are eligible for this study and there will not have been any detectable spread of their tumor on imaging studies following this chemotherapy course.

Conditions

  • Unresectable Pancreatic Cancer

Interventions

RADIATION

Radiation Therapy

Radiation therapy dose escalation to an MR-defined gross tumor volume (GTV) of up to 69.75 Gy at 2.25 Gy per fraction.

DRUG

Concurrent chemotherapy (Gemcitabine, Capecitabine)

Gemcitabine 400mg/m\^2 IV weekly x 6 doses. Capecitabine 825 mg/m\^2 by mouth twice daily Monday-Friday on days of radiation use 500 mg tablets.

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Beth Erickson, MD · Froedtert & The Medical College of Wisconsin

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-10
Primary Completion
2023-12-13
Completion
2026-11-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01972919 on ClinicalTrials.gov